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‘Smooth seas do not make 
skilful sailors.’ (African 
proverb)
For 3 stormy years from 
the time Tugela Ferry’s doc-
tors first uncovered what turned out to 
be an alarming countrywide extensively 
drug-resistant tuberculosis (XDR-TB) 
prevalence (2005 - 2007), they diagnosed 
110 new XDR-TB cases per year. Yet by 
implementing a combination of interven-
tions with a remarkable team, the tap was 
turned down to less than 10 cases in 2012, 
making the Church of Scotland Hospital 
(CoSH) an international beacon of best 
practice. Izindaba returned there after 6 
years to find out how they are helping to 
quell the general TB epidemic itself.
Just a few months short of 60 years old, 
Thengokwakhe Nkala, a former migrant 
worker from rural KwaZulu-Natal (KZN), 
has been to hell and back.
His sunken eyes and a humble demeanour 
are as much clues to his massively against-
the-odds survival of XDR-TB as they are a 
reflection of the harshly hot, rocky thornveld 
in which he, his wife and eight children 
eke out a living near Tugela Ferry. All he 
knows of the 85% XDR-TB death rate among 
hundreds of fellow patients at Tugela Ferry’s 
CoSH between 2005 and now is that ‘a lot’ 
of people like him who were transferred to 
King George V Hospital (Durban) suffering 
from multidrug-resistant (MDR)- or XDR-
TB died. ‘Aba-sekho’ (they are no longer 
with us), he shrugs with a millennia-old 
acceptance of Africa’s cruel mysteries. His 
coughing began while he was working 
at a cement factory in Johannesburg and 
rapidly became so bad that he returned 
home ‘when I felt my strength had gone’ in 
2008. He reported to CoSH within months, 
a fortuitous 3 years after tenacious medical 
detective work by its doctors had helped 
identify ‘XDR’-TB as responsible for the 
deaths of 52 of the 53 local inpatients whose 
sputum culture tests resisted every drug 
thrown at them (by Durban’s Nkosi Albert 
Luthuli Hospital laboratory technicians) 
in 2005. Nkala’s quick transfer to the 
TB-specialising King George V Hospital was 
a last-gasp hope, driven by the slim chance 
that a correct diagnosis and appropriate 
combination of drugs, plus sheer good luck, 
might work. He spent 18 months in an 
isolation ward, enduring 160 injections of 
kanamycin over 6 months, along with an oral 
TB and HIV drug regimen, often writhing 
in pain and discomfort from the debilitating 
side-effects as he dimly watched members 
of his clan and tribe daily breathe their last 
alongside him. 
Unbroken tradition
The remote 83-year-old, 350-bed KZN 
district hospital, founded by Scottish doctor-
missionary, George William Gale on what 
was the Zululand side of the Tugela River 
(then linked to Natal by a rope-spanned 
ferry), has a history of selfless, dedicated 
service by Christian doctors to the estimated 
200 000 traditional Zulus of Msinga, the 
poorest subdistrict in the country. The latest 
embodiments of this altruistic culture are Drs 
Tony Moll and Francois Eksteen, veterans of 
28 years and 18 years respectively at CoSH. 
Moll currently heads the local antiretroviral 
(ARV) programme and with his wife Debbie, a 
local school principal, has raised four children 
here. Eksteen manages clinical care for the 
hospital’s nearly 80 TB inpatients and consults 
weekly at the specialised MDR-TB clinic in 
Greytown. Both went for ARV drug training 
under Prof. Gerald Friedland (Epidemiology 
and Public Health) at Yale University as 
early as 2003. That decision enabled CoSH 
to quietly provide ARVs to 100 patients, 
the drugs coming from Yale. The first sign 
that the AIDS-denying late Health Minister 
Dr  Manto Tshabalala-Msimang would yield 
to international pressure came a year later – 
via an official international-media-attended 
ARV ‘launch’ at CoSH, the first public hospital 
to provide ARVs on the national rollout (just 
one month before the April 2004 national 
elections). Patients flooded in, mostly with 
CD4 counts dangerously below 100 cells/µL 
(today the ARV inception threshold is 500/
µL) and among them a small but significant 
percentage carrying undiagnosed MDR- 
and XDR-TB, creating the ‘perfect storm’ 
for nosocomial spread. As the TB-drug-
resistant contagion multiplied, the doctors 
were carefully monitoring all ARV treatment 
side-effects, CD4 cell counts and viral loads, 
witnessing mostly astounding improvements 
(after 13 years of AIDS palliative care). Many 
AIDS patients were too far advanced, but 
if they managed 3 months on ARVs before 
succumbing to opportunistic infections, 
the disease usually turned around and they 
survived. Moll and Eksteen noticed two 
patients (initially) whose CD4 cell counts 
stubbornly (and unusually) refused to budge, 
their viral loads remaining suppressed. Their 
opportunistic infections were being treated – 
but signs and symptoms of TB continued, ‘so 
we immediately thought of MDR-TB’, says 
Moll. Two university student interns needed 
a project, ‘so I said set up a table and do a 
specimen snapshot of every single coughing 
in- and outpatient’. Some 45 samples were 
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‘Miracle’ XDR-TB survivor Thengokwakhe Nkala, 59, Sr Hlezi Bengu and Dr Tony Moll. All photos by 
Chris Bateman.
By October 2006, CoSH had 
diagnosed over 200 XDR-TB 
cases, the highest number at any 
single hospital on the planet, 
and with emerging figures from 
across the globe, the WHO called 
a summit in Geneva where Moll 
presented the team’s findings, 
and the current definition of 
XDR-TB was coined.
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sent off to the Durban lab, and in May 
2005 Moll received an alarmed call from 
chief pathologist Dr Lynne Roux, saying 
that six of the samples resisted every drug 
thrown at them – and that four other samples 
from Greytown and Durban had behaved 
identically. Their two MDR suspects were 
in the group. Provincial and national case 
finding began in earnest. By 2007 some 60 
KZN health facilities were identified as having 
patients with XDR- and MDR-TB, a survey 
of 19 of them a year later showing an average 
of 15% MDR-TB and 3% XDR-TB among 
confirmed TB patients. National data from 
across all nine provinces in 2007 revealed 
1  000 XDR-TB cases and 7 350 MDR-TB 
cases, almost certainly the tip of an iceberg.
Unmatched initial XDR 
infections
By October 2006, CoSH had diagnosed over 
200 XDR-TB cases, the highest number at 
any single hospital on the planet, and with 
emerging figures from across the globe, the 
World Health Organization (WHO) called a 
summit in Geneva where Moll presented the 
team’s findings, and the current definition 
of XDR-TB was coined. With international 
interest focused on Tugela Ferry, attracting 
operational research funding, a strong 
collaboration was being formed at CoSH 
including partners from Yale (Profs 
Friedland, Gandhi, Shah and Shenoi), the 
University of KZN (Prof. Sturm), an Italian 
corporation (Dr Marra), the provincial 
TB office (Dr Margot), the local district 
manager (Mr Mndebele), and many others 
who joined later. 
‘Without technical assistance from this 
amazing team and support from the DOH, 
we would not have been able to crunch this 
rock or roll it away as we have done,’ says 
Moll. ‘With a virtually untreatable airborne 
infection in our midst, this put us healthcare 
workers into another league of danger and 
vulnerability.’ The team immediately upped 
surveillance, resulting in the now famously 
documented 53 positive cultures, half of 
whose owners had died by the time the results 
came back 6 weeks after sputum collection. 
Even scarier, 26 of them had never had 
TB before, indicating first-time presentation 
with XDR-TB. By 2009, when CoSH’s XDR 
numbers had grown to 500 (98% of them 
HIV-positive), ‘we (seemingly paradoxically) 
relaxed a bit; it showed us that it wasn’t 
so transmissible after all’. The transmission 
was in fact mostly nosocomial, requiring 
drastic infection control measures, including 
isolation and fast-tracking of coughing 
patients. Every worker in the hospital high-
risk areas wears an N95 mask and outpatients 
sit in decongested, airy, sheltered outdoor 
waiting areas. Infection control officers and 
nurses monitor constantly, ensuring that all 
windows remain open.
XDR/MDR-TB down  
by 90%
XDR/MDR-TB prevalence in the surr-
ounding Msinga area has dropped by 90%. 
Going back to basics, the team intervened 
immediately at community level by 
screening over 3 200 household contacts of 
614 drug-resistant (DR) index patients and 
launching a community intensified case-
finding project. Dr Vijay Guddera, research 
manager at Philanjalo, CoSH’s research and 
step-down NGO-funded facility (a hospice 
in the pre-ARV era), told me that intensive 
Married Zulu women break into dance at an 
outreach clinic near Tugela Ferry.
Sr A R Zungu, District Programme Manager for 
Umzinyathi in KwaZulu-Natal. 
MDR-TB researcher Dr Vijay Guddera and Church of Scotland Hospital Clinical Manager, Dr Tony Moll.
Nurse Thandeka Shabalala with her thriving MDR-
TB patient, Silindile Mbatha, after administering 
her daily kanamycin injection at home.
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case finding has resulted in 15 000 people 
being screened since 2010 at community 
congregate settings, with the advantage of 
bringing patients into care earlier. In the 
local prison it took 38 people to find one TB 
case, in the taxi ranks one in 140 and at the 
local schools one in 240. In some months up 
to 30 new DR cases were identified at CoSH, 
which placed an unmanageable load on the 
provincial King George V MDR-TB hospital 
in Durban. Moll says, ‘Often patients had to 
wait up to 6 weeks to get a bed in Durban 
where they could start treatment, some 
dying while waiting.’ 
This gave birth to the province’s first 
MDR-TB ‘decentralised’ hospital, also the 
first in the country, which is now in full 
swing in nearby Greytown, a 45-minute 
mountainous drive away. It is here that I once 
again meet Moll, 6 years after spending two 
nights at his CoSH home while confronting 
the full reality of what was portrayed in the 
lay media as an XDR-TB ‘outbreak’ (what 
the CoSH team found merely epitomised the 
unseen national contagion that is today an 
even greater threat than HIV, the precursor 
MDR-TB pandemic having doubled in size 
and XDR-TB prevalence slowly burgeoning). 
Greytown is a small farming village nestled 
among dairy, beef and crop farms and 
sprawling timber plantations in misty, green, 
rolling countryside, dramatically different 
to the harsh Tugela valley below. It now 
hosts the hospital lifeline for MDR-TB 
and pre-XDR-TB patients. Simply called 
M3, it was rededicated as an exclusive 
37-bed MDR-TB hospital in 2007, rolling 
out treatment in February the following 
year. Subsequently several similar MDR-
TB hospitals have opened in South Africa, 
reducing the major current bed shortages 
but ‘de-institutionalising’ MDR/XDR-TB 
management. (According to national MDR-
TB chief Dr Norbert Ndjeka, nearly half 
of all diagnosed cases are not started on 
treatment and patients wait up to 2 months 
for admission.) As much as political AIDS 
denialism delayed ARVs, unnecessarily 
costing countless lives, the triumph of quick 
intervention when a deadly disease is detected 
is epitomised by Greytown’s M3 MDR-TB 
hospital. Fast diagnosis and swift initiation 
of effective treatment is essential, as patients 
respond better with early treatment and 
soon stop transmitting disease. A full 85% of 
patients are smear-negative after 2 months of 
treatment. GeneXpert testing for rifampicin 
resistance has doubled MDR-TB diagnostic 
accuracy and hugely reduced the time to 
treatment initiation (from 2 months to just 
48 hours). Ninety per cent of all sputum 
specimens sent from all facilities in the 
Umzinyathi District (which Greytown M3 
covers as an MDR-TB referral facility) were 
returned within 48 hours last year, allowing 
treatment of smear-positive patients to begin 
immediately. 
After a short admission to M3, patients 
are discharged to the novel Community 
Management of MDR-TB Programme and 
cared for in their own homes by outreach 
teams arriving in rugged-terrain vehicles 
and doing daily home-based administration 
of the injections, screening and educating 
family members, and monitoring for any 
side-effects. Initially there were 13 outreach 
teams – now only four are needed. The huge 
success of this programme has its essence 
in the caring community support wrapped 
around each patient going through those 
tough, long 18 - 24 months of treatment, 
resulting in improved patient satisfaction 
and excellent outcomes. The programme 
has become a national DR/XDR-TB bench-
mark model. The University Research 
Council came on board and bankrolled a 
2-year mentoring programme for satellite 
and decentralised sites in eight other 
provinces, with most provinces (and several 
international institutions) sending their top 
TB and HIV managers and clinicians to 
learn the ropes at CoSH and Greytown. 
I ask Eksteen, who comes up from the 
valley once a week to conduct a clinic at M3, 
what he’d do if he had a ‘magic wand’. The 
answer is unsurprising to any TB healthcare 
worker who’s seen patients die while awaiting 
lab results (or started them too soon on 
inappropriate treatment). ‘Well, we don’t have 
a second-line PCR test yet – I’m not sure 
whether it’s a validation problem or the cost 
factor or a combination of the two. If we 
did, it would make a huge difference to 
MDR-TB patient Silindile Mbatha, 30, could hardly walk when CoSH outreach team nurse Thandeka 
Shabalala began visiting her for her daily kanamycin injection in her wattle-and-daub Upper Msinga 
home in November last year. Weak and jaundiced, her initial X-rays at the local clinic were inconclusive 
so she was sent to CoSH where the GeneXpert test confirmed MDR-TB. ‘I think I got it when I was 
working in Jeppe in Gauteng in 2013 (a known MDR-TB ‘hot-spot’) – it was very overcrowded and 
unhygienic there,’ she says. Mbatha’s weight has increased from 67.8 kg to 69.8 kg since her injection 
and pill home treatment started – ironically in a far-flung rural district that normally spells death for 




































Umzinyathi District turnaround times (percentage returned within 48 hours) for sputum specimen results.
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XDR patients. I know they were thinking 
of a GeneXpert type office test on site for 
fluoroquinolones, I don’t know how far that 
is. The ideal would be to have the GeneXpert 
PCR test for fluoroquinolones in a kind of 
“black box” where you put the specimen in 
one side and get the result out the other side 
in a matter of hours.’ Eksteen says if a patient 
with MDR-TB walks into hospital today, it 
can take up to 3 months to diagnose XDR-TB. 
If he starts an XDR patient on MDR treatment 
there may be some effect if ‘one or two drugs 
are working, but in principle you need three 
or more drugs to have a quick outcome. 
A deficient regimen, and the patient can 
deteriorate badly and your options become 
severely limited’ (death being the most likely 
outcome). Most of Greytown’s M3 referrals 
come from the Charles Johnson Memorial 
Hospital in Nqutu; CoSH sends slightly fewer, 
Dundee and Umvoti hospitals the least. A fleet 
of emergency medical rescue service (EMRS) 
buses transports both ‘cold’ and emergency 
cases from these sub-districts – and more 
recently from Ladysmith, Estcourt and 
Emmaus in the Tugela district, plus Illembe 
near Stanger, closer to the coast. I put the 
‘magic wand’ question to veteran Sister Lee-
Megan Larkan, who runs the MDR-TB clinic 
at M3 which sees 70 referred patients every 
Wednesday. ‘To be able to decant patients 
from here to the satellite units once they’re 
stable (especially if the satellite hospital team 
has outreach injection capacity). Also to fast-
track nurse-initiated management TB-drug-
resistance training so we can have nurses at 
satellite units who can look after the patients. 
We have challenges with transport, so if the 
care can be decentralised, it can be within 
walking distance.’ Another high priority/
unmet need is overnight accommodation 
for patients, who currently sleep in a chair or 
on the floor at the outpatients area of their 
subdistrict hospital before catching the EMRS 
bus to Greytown the next day. If they’re late 
getting their MDR-TB treatment at M3, they 
again sleep in whatever sheltered area they 
can find around or near the hospital before 
catching the bus. However, the most effective 
solution, says Larkan, would be to get the 
satellite sites up and running properly to 
decrease the M3 workload. ‘In that way we 
could start managing XDRs here. Waiting for 
a bed at King George can nowadays take up 
to 3 weeks and it’s detrimental to the patients.’ 
Eksteen affirms this, ‘Ideally one would like 
to initiate XDR treatment at the decentralised 
hospitals.’ 
Yet they’re obviously doing something 
right; initially nearly half of all Greytown’s 
MDR-TB patients were pre-XDR, now it’s 
down to about 15%. The average inpatient 
stay is 4 - 6 weeks, compared with 4 months 
when the facility opened 7 years ago. This 
is almost entirely due to CoSH’s outreach 
injection/home-based care programme 
being closely emulated in the other three 
satellite feeder health districts, plus improved 
drug adherence counselling. TB prevalence 
in CoSH’s Msinga district stands at 
1 000/100 000 population (about the national 
average, the WHO attributing ‘emergency 
status’ to any country at 250/100  000 or 
above).
The team has contributed heavily to the 
national guidelines for community manage-
ment of MDR-TB and the decentralisation 
of MDR-TB services. Umzinyathi healthcare 
workers are saving lives hand over fist (the 
target being 85%); the overall Umzinyathi 
district treatment success rate for all regular 
TB cases was 86.2% in 2011. Last year it was 
88.4%. For CoSH in 2011 it was 86.4%. Last 
year it was 91%. The district’s ‘suspicion 
index’ (percentage of patients suspected of 
having TB, irrespective of what services 
they come for) stands at 4%, the target being 
5 - 10%.
Living proof of what self-help author and 
counsellor Douglas Bloch was once quoted 




1. Mitchell J. If you’re going through hell, don’t stop! (newspaper 
interview with Douglas Bloch). The Oregonian, 18 November 
1990. (Full quote: ‘When someone says, “I’m going through
hell,” the best response is to say, “Don’t stop!” If we see that pain, 
grief and tough times are a process and that it will get better, 
we’re less likely to get stuck in the hell.’)








































Umzinyathi District cure rates for MDR- and XDR-TB.
